Medical College of Wisconsin, Milwaukee.
US Centers for Disease Control and Prevention, Atlanta, Georgia.
JAMA Dermatol. 2022 Jun 1;158(6):626-633. doi: 10.1001/jamadermatol.2022.0828.
Vaccine-derived and wild-type rubella virus (RuV) has been identified within granulomas in patients with inborn errors of immunity, but has not been described in granulomas of healthy adults.
To determine the association between RuV and atypical granulomatous inflammation in immune-competent adults.
DESIGN, SETTING, AND PARTICIPANTS: This case series, conducted in US academic dermatology clinics from January 2019 to January 2021, investigated the presence of RuV in skin specimens using RuV immunofluorescent staining of paraffin-embedded tissue sections, real-time reverse-transcription polymerase chain reaction, whole-genome sequencing with phylogenetic analyses, and cell culture by the US Centers for Disease Control and Prevention. Rubella immunoglobulin G, immunoglobulin M enzyme-linked immunoassay, and viral neutralization assays were performed for the sera of immunocompetent individuals with treatment refractory cutaneous granulomas and histopathology demonstrating atypical palisaded and necrotizing granulomas. Clinical immune evaluation was performed.
Identification, genotyping, and culture of vaccine-derived and wild-type RuV within granulomatous dermatitis of otherwise clinically immune competent adults.
Of the 4 total immunocompetent participants, 3 (75%) were women, and the mean (range) age was 61.5 (49.0-73.0) years. The RuV capsid protein was detected by immunohistochemistry in cutaneous granulomas. The presence of RuV RNA was confirmed by real-time reverse-transcription polymerase chain reaction in fresh-frozen skin biopsies and whole-genome sequencing. Phylogenetic analysis of the RuV sequences showed vaccine-derived RuV in 3 cases and wild-type RuV in 1. Live RuV was recovered from the affected skin in 2 participants. Immunology workup results demonstrated no primary immune deficiencies.
The case series study results suggest that RuV (vaccine derived and wild type) can persist for years in cutaneous granulomas in clinically immunocompetent adults and is associated with atypical (palisaded and necrotizing type) chronic cutaneous granulomas. These findings represent a potential paradigm shift in the evaluation, workup, and management of atypical granulomatous dermatitis and raises questions regarding the potential transmissibility of persistent live RuV.
在先天性免疫缺陷患者的肉芽肿中已鉴定出疫苗衍生和野生型风疹病毒(RuV),但在健康成年人的肉芽肿中尚未描述。
确定 RuV 与免疫功能正常成年人中非典型肉芽肿性炎症之间的关联。
设计、地点和参与者:本病例系列研究于 2019 年 1 月至 2021 年 1 月在美国学术皮肤科诊所进行,使用 RuV 免疫荧光染色石蜡包埋组织切片、实时逆转录聚合酶链反应、全基因组测序和与美国疾病控制与预防中心的系统发育分析,以及细胞培养来检测皮肤标本中 RuV 的存在。对治疗抵抗性皮肤肉芽肿和组织病理学表现为非典型栅栏状和坏死性肉芽肿的免疫功能正常个体的血清进行风疹免疫球蛋白 G、免疫球蛋白 M 酶联免疫吸附测定和病毒中和测定。进行了临床免疫评估。
在其他临床免疫功能正常的成年人的肉芽肿性皮炎中鉴定、基因分型和培养疫苗衍生和野生型 RuV。
在 4 名免疫功能正常的参与者中,3 名(75%)为女性,平均(范围)年龄为 61.5(49.0-73.0)岁。免疫组织化学法在皮肤肉芽肿中检测到 RuV 衣壳蛋白。实时逆转录聚合酶链反应在新鲜冷冻皮肤活检和全基因组测序中证实了 RuV RNA 的存在。RuV 序列的系统发育分析显示 3 例为疫苗衍生 RuV,1 例为野生型 RuV。2 名参与者从受影响的皮肤中恢复了活 RuV。免疫学研究结果表明不存在原发性免疫缺陷。
病例系列研究结果表明,RuV(疫苗衍生和野生型)可在临床免疫功能正常的成年人的皮肤肉芽肿中持续存在数年,并与非典型(栅栏状和坏死型)慢性皮肤肉芽肿相关。这些发现代表了对非典型肉芽肿性皮肤病评估、检查和管理的潜在范式转变,并提出了关于持续活 RuV 潜在传染性的问题。